_transparent-small%20(1).png){kind=spacer}
.png)
This activity is jointly provided by Medical Education Resources and California Society of Dermatology & Dermatologic Surgery.
Accreditation Statement In support of improving patient care, this activity has been planned and implemented by Medical Education Resources (MER) and the California Society of Dermatology and Dermatologic Surgery. MER is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team Nursing Credit Medical Education Resources designates this live activity for a maximum of 14.25 ANCC nursing contact hours. Nurses will be awarded contact hours upon successful completion of the activity. | 
Physician Associates Credit Medical Education Resources has been authorized by the American Academy of Physician Associates (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 14.25 AAPA Category 1 CME Credits. Physician Associates should only claim credit commensurate with the extent of their participation. Physician Credit Medical Education Resources designates this live activity for a maximum of 14.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. |
Program Overview:
This educational activity is designed to address key knowledge and skill gaps in medical, surgical, and practice-based dermatology. As advancements in therapeutics, technology, and healthcare policy continue to evolve, dermatology professionals must stay current on best practices in patient care, procedural techniques, and regulatory changes. The program features a comprehensive range of topics, including inflammatory skin disease, alopecia, psoriasis, cosmetic and surgical dermatology, and emerging tools such as artificial intelligence. Through expert-led sessions and case-based learning, this activity supports continuous professional development and aims to improve patient outcomes in a rapidly changing healthcare environment.
Target Audience: This activity has been designed to meet the educational needs of dermatologists, dermatology residents, and other healthcare professionals involved in the diagnosis and management of medical, surgical, and cosmetic dermatologic conditions.
Educational Objectives After completing this activity, the participant should be better able to: 1. Identify effective management strategies for psoriasis, including treatment-resistant cases and emerging insights such as immune drift that influence long-term therapy selection. 2. Select appropriate medical and surgical treatments for vitiligo, including correct regimens and available surgical options. 3. Evaluate and manage hidradenitis suppurativa using outpatient deroofing procedures, including patient selection and technique application. 4. Discuss treatment considerations and management pearls for infantile hemangiomas, including ulcerated presentations. 5. Apply knowledge of vulvar microanatomy to distinguish between vulvar dermatoses. | 6. Assess moderate to severe alopecia areata using the Alopecia Areata Severity Scale and identify emerging and multimodal therapies for androgenetic alopecia. 7. Recognize psychosocial needs of vulnerable populations (including digitally native adolescents and young adults) and apply appropriate early interventions. 8. Implement evidence-based dermatologic therapies, including JAK inhibitors (uses, risks, benefits), emerging topical treatments, and management of contact allergens and GLP-1 RA–related cosmetic effects. 9. Apply consensus methods appropriately, manage bias and conflicts of interest, and improve office efficiency through staff training and patient education materials. 10. Optimize dermatologic surgical care through procedural pearls, wound closure assessment, appropriate biopsy selection, recognition of key immunopathologic conditions, and counseling on thread-lift complications. |
Disclosure of Relevant Financial RelationshipsMedical Education Resources ensures balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, MER identifies all financial relationships with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Reported relevant financial relationships are mitigated by MER to ensure that all scientific research referred to, reported, or used in a CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. MER is committed to providing learners with high-quality CE activities that promote improvements or quality in health care and not the business interest of an ineligible company. |
|
Name of Faculty |
Reported Financial Relationship |
|
Dawn Siegal, MD |
Eli Lilly - Advisory Board atopic dermatitis |
|
April W. Armstrong, MD |
Bristol-Myers Squibb; Janssen; Novartis; Takeda - Researcher Abbvie; Amgen; Arcutis; Bristol-Myers Squibb; Dermavant Sciences; Eli Lilly and Company; Galderma; Janssen; LEO Pharma; Novartis; Pfizer; Regeneron; Sanofi; UCB; Incyte - Consultant Janssen; Eli Lilly and Company; Galderma; Regeneron - Speaker |
|
Matthew Lewis |
AbbVie; Regeneron; Galderma - Speaker |
|
Jennifer Fu, MD |
Eli Lilly - Consultant; Pfizer - Investigator, Consultant; Sun Pharmaceuticals - Consultant; Adelphi Real World - Investigator; LearnSkin - Instructor |
|
Kasha Hunt |
Bristol Myers Squibb - Consultant; Kerecis - Consultant |
|
Tina Bhutani, MD |
Amgen, Castle, CorEvitas, Novartis, Pfizer, and Regeneron - Research Abbvie, Apogee, Arcutis, Aslan, Boehringer-Ingelheim, Bristol Myers Squibb, Castle, Dermavant, Galderma, Incyte, Janssen, LEO, Eli Lilly, Oruka, Pfizer, Novartis, Regeneron, Sanofi, Sun, Takeda, Taxa, and UCB - Advising Abbvie, Amgen, Arcutis, BMS, Dermavant, Galderma, Janssen, Lilly, LEO, Mindera, Ortho, Pfizer, Regeneron, Sanofi, and UCB - Speaker |
|
Angela Blanchard |
Bristol Myers Squibb - Consultant; Kerecis - Consultant |
|
Silvina Pugliese, MD |
Regeneron, - US Non-Melanoma Skin Cancer Advisory Board |
|
Shehla Admani, MD |
Arcutis, Eli Lilly, and LEO - Consultant |
|
Amit G Pandya, MD |
Avita, Inctye - Investigator & Consultant |
|
Paradi Mirmirani, MD |
Pfizer - Advisory board and investigator |
|
Mary Horner, MD |
Abbvie, Galderma, Sanofi/Regeneron, Eli Lilly, UCB - Speaker |
|
Serena Mraz, MD |
Galderma - Trainer |
|
Smitha Awasthi, MD |
Pfizer - Principal Investigator (abrocitinib in atopic dermatitis) |
|
Sungat Kaur Grewal, MD |
Candela - Key Opinion Leader |